Entos, creator of a platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, announced the closing of a $53 million Series A financing round led by Coatue and Catalio Capital Management; with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.

Founded in 2019, Entos is focused on disrupting therapeutic discovery with OrbNet, its platform combining AI-driven technology and automated synthetic development to rapidly design small-molecule therapeutics.